BioCentury | Nov 16, 2019
Company News

Management tracks: Lonza CEO to step down; plus Arrowhead, Insmed, Inozyme, Yukin, Pfenex, EyePoint, Verseau, Abingworth, CBC, Flagship, Diverse, Theragnostics,

...Changchun Changsheng Bio-technology Co. Ltd. vaccine scandal and expelled from the Communist Party in February. Yukin Therapeutics...
...N.V. (NASDAQ:AFMD). Jonathan Block, Associate Editor Jonathan Block, Associate Editor, and Hongjiang Li, Staff Writer Lonza Group Ltd. Insmed Inc. Yukin Therapeutics Pfenex...
BioCentury | Jul 18, 2019
Financial News

Medicxi’s new €400M fund unites early, late stage investing

...Phathom Pharmaceuticals LLC (Menlo Park, Calif.); ocular cancer play Aura Biosciences Inc. (Cambridge, Mass.); and Yukin Therapeutics...
BioCentury | Jun 21, 2019
Finance

VC pair seeds cancer play Yukin, seeks preclinical readout

...within a year. Co-founded last year by Advent and technology transfer office SATT Sud-Est, Nice-based Yukin Therapeutics...
...program could be differentiated because it is an allosteric modulator of the target. Paul Bonanos, Associate Editor Yukin Therapeutics...
Items per page:
1 - 3 of 3
BioCentury | Nov 16, 2019
Company News

Management tracks: Lonza CEO to step down; plus Arrowhead, Insmed, Inozyme, Yukin, Pfenex, EyePoint, Verseau, Abingworth, CBC, Flagship, Diverse, Theragnostics,

...Changchun Changsheng Bio-technology Co. Ltd. vaccine scandal and expelled from the Communist Party in February. Yukin Therapeutics...
...N.V. (NASDAQ:AFMD). Jonathan Block, Associate Editor Jonathan Block, Associate Editor, and Hongjiang Li, Staff Writer Lonza Group Ltd. Insmed Inc. Yukin Therapeutics Pfenex...
BioCentury | Jul 18, 2019
Financial News

Medicxi’s new €400M fund unites early, late stage investing

...Phathom Pharmaceuticals LLC (Menlo Park, Calif.); ocular cancer play Aura Biosciences Inc. (Cambridge, Mass.); and Yukin Therapeutics...
BioCentury | Jun 21, 2019
Finance

VC pair seeds cancer play Yukin, seeks preclinical readout

...within a year. Co-founded last year by Advent and technology transfer office SATT Sud-Est, Nice-based Yukin Therapeutics...
...program could be differentiated because it is an allosteric modulator of the target. Paul Bonanos, Associate Editor Yukin Therapeutics...
Items per page:
1 - 3 of 3